Merck Animal Health is not just a company. It’s where the science of healthy animals meets the commitment of horse health professionals. We work every day to bring you innovative products and trusted support. We are building on a rich history of providing animal health solutions. However, to help solve the challenges equine veterinarians face, we’re not resting on our history alone. Merck Animal Health continues to make significant investments in research and development each year.

“The science behind our protection builds off a rich history of innovation but doesn’t stop there. Our researchers are behind the scenes looking for tomorrow’s solutions. We’re listening to what horse owners are concerned with and anticipating tools veterinarians will need. I’m proud of our portfolio today and even more excited about how it will look in the future.”

Wendy E. Vaala, V.M.D., Dipl. ACVIM
Merck Animal Health
Innovation Backed by Science You Can Trust

Antigen Purification System™
A vaccine can never be too safe. Our technology, known as the Antigen Purification System (APS), has been utilized for more than 20 years to help remove extraneous protein and cellular debris. Using this method of filtration purification allows concentration of antigen while minimizing the presence of extraneous protein and cellular debris that can contribute to vaccine-associated adverse events. By purifying the vaccines with the APS, we reduce the debris that can cause undesirable injection site reactions in the horse.

Exclusive Havlogen® Adjuvant
Our killed vaccines are highly efficacious, in part, because of our exclusive Havlogen adjuvant. Havlogen is an emulsive, lipid-based, carbopol polymer cross-linking adjuvant. Havlogen stimulates the immune system to produce high, long-lasting levels of protection through the slow release and gradual absorption of antigen. Due to the composition of Havlogen, the vaccine maintains suspension without separation and settling in the vial—resulting in consistency and potency in every dose. By combining our APS system and Havlogen adjuvant, we are able to produce a line of killed virus vaccines that are highly efficacious and have an exceptional safety profile—shown to be 98% reaction-free in field safety trials1.


“...The only thing a vaccine should provide is protection. That’s why Merck uses state-of-the-art technology in all its products to minimize risk of reactions and provide consistency in each and every dose.”

D. Craig Barnett, D.V.M.
Merck Animal Health Equine Professional Services
Vaccines

PRESTIGE® 5 + WNV ENCEPHALOMYELITIS - RHINOPNEUMONITIS - INFLUENZA - WEST NILE VIRUS VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against Eastern and Western encephalomyelitis viruses, EHV-1, EHV-4, tetanus, and West Nile Virus. Duration of immunity has been shown at six months for EIV. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

Duration of immunity has been shown at six months for EIV. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.**

1 x 10 mL, 10 x 1 mL

PRESTIGE® 3 ENCEPHALOMYELITIS VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against Eastern and Western encephalomyelitis viruses, EHV-1, EHV-4, and tetanus. Duration of immunity has been shown at six months for EHV-1, EHV-4, and tetanus. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL, 10 x 1 mL

PRESTIGE® 2 EQUIINE RHINOPNEUMONITIS - INFLUENZA VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against EIV, EHV-1 and EHV-4. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL, 10 x 1 mL

PRESTIGE® EHV 1 & 4 EQUIINE RHINOPNEUMONITIS - INFLUENZA VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against EIV and EHV-1. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL

PRESTIGE® WNV WEST NILE VIRUS VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against West Nile Virus. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL, 10 x 1 mL

PRESTIGE® 3 + WNV ENCEPHALOMYELITIS - WEST NILE VIRUS VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against Eastern and Western encephalomyelitis viruses, tetanus and West Nile Virus. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL, 10 x 1 mL

PRESTIGE® Prodigy® EQUIINE RHINOPNEUMONITIS VACCINE

This product has been shown to be effective for the vaccination of healthy horses six months of age or older against abortion and respiratory disease caused by EHV-1. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 20 mL, 10 x 1 mL

PRESTIGE® Tetanus TETANUS TOXOID

This product has been shown to be effective for the vaccination of healthy horses four months of age or older against tetanus. Duration of immunity has been shown at six months of age or older against tetanus. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 1 mL

Flu Avert® I.N. EQUIINE INFLUENZA VACCINE

This product has been shown to be effective for the vaccination of healthy horses 15 months of age or older against disease caused by EIV. Duration of immunity has been shown to be at least 6 months. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

This product has been shown to be effective against virus shedding of EIV. 1 x 1 mL

**This product has been shown to be effective against virus shedding of EIV and EHV-1.

For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

1 x 10 mL, 10 x 1 mL

Vaccine Chart

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Tetanus</th>
<th>WNV</th>
<th>Rabies</th>
<th>EEE/WEE</th>
<th>Influenza</th>
<th>EHV 1 &amp; 4</th>
<th>EHV-1 Abortion</th>
<th>Respiratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige® 5 + WNV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® EHV 1 &amp; 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® WNV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® 3 + WNV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® Prodigy®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prestige® EquiRab®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flu Avert® I.N.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Dolorex

(Doripenem for injection)


PHARMACOLOGY

Doripenem is a broad-spectrum beta-lactam antibiotic that is indicated for the treatment of infections caused by: (1) Acinetobacter species, including A. baumannii, A. nosocomialis, A. lwoffii, A. calcoaceti, A. baylyi, A. baumannii, and A. rhinitis; (2) A. baumannii, A. nosocomialis, A. lwoffii, A. calcoaceti, A. baylyi, A. baumannii, and A. rhinitis; (3) A. baumannii, A. nosocomialis, A. lwoffii, A. calcoaceti, A. baylyi, A. baumannii, and A. rhinitis; and (4) A. baumannii, A. nosocomialis, A. lwoffii, A. calcoaceti, A. baylyi, A. baumannii, and A. rhinitis.

SIDE EFFECTS

Dolorex has been shown to be generally well tolerated in clinical trials.

INTERACTIONS

Dolorex is contraindicated in patients with a history of hypersensitivity to doripenem or any other member of the penam class of antibiotics.

WARNINGS AND PRECAUTIONS

Dolorex is contraindicated in patients with a history of hypersensitivity to doripenem or any other member of the penam class of antibiotics.

PROTECTIONS

Dolorex is contraindicated in patients with a history of hypersensitivity to doripenem or any other member of the penam class of antibiotics.

CAUTION

Dolorex is contraindicated in patients with a history of hypersensitivity to doripenem or any other member of the penam class of antibiotics.

FOR VETERINARY USE ONLY

Dolorex is contraindicated in patients with a history of hypersensitivity to doripenem or any other member of the penam class of antibiotics.

DOSAGE AND ADMINISTRATION

The recommended dosage of Doripenem for injection is 500 mg IV as a single daily dose for adults and children 12 years of age and older, and 250 mg IV as a single daily dose for children under 12 years of age. Doripenem for injection should be administered as a 30-minute intravenous infusion in the hospital setting.

REFERENCES


BANAMINE PASTE

Horse Weight

For: Oral use in Horses Only

CALCULATIONS: When calculating dosage, the dose may be determined by weight. Therefore, the dosage of BANAMINE Paste should be calculated based on the individual horse's weight.

DESCRIPTION

BANAMINE Paste is a concentrate of BANAMINE, a nonsteroidal anti-inflammatory drug (NSAID) which is indicated for the treatment of lameness and swelling in the horse. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

PHARMACOLOGY

BANAMINE Paste contains BANAMINE, a nonsteroidal anti-inflammatory drug (NSAID) which is indicated for the treatment of lameness and swelling in the horse. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

SIDE EFFECTS

BANAMINE Paste may have the following side effects: vomiting, diarrhea, increased use of water, decreased appetite, and decreased food intake.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


CAUTION

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

DOSAGE AND ADMINISTRATION

The recommended dosage of BANAMINE Paste is 0.5 ml or 1 ml per 30 kg of body weight, administered by rectal injection. BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

REFERENCES


PROTECTIONS

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.

FOR VETERINARY USE ONLY

BANAMINE Paste is contraindicated in horses with a history of hypersensitivity to BANAMINE or any other member of the phenylbutyazone class of drugs.
The intravenous route produces the most rapid diuretic effect. Oral thiazide diuretics are absorbed systemically in animals, and the rapid intravenous route is contraindicated in management of potassium depleting diuretics that may cause symptomatic hypokalemia.

The most rapid diuretic effect may be obtained by intravenous administration. Oral diuretics are absorbed systemically, while the rapid intravenous route is contraindicated in management of potassium depleting diuretics which may cause symptomatic hypokalemia.

Salix is indicated for the treatment of dermatological and cutaneous diseases, particularly those affecting the skin and mucous membranes. If Swallowed: Do not induce vomiting. Regu-Mate may be given to treat a variety of diseases affecting the skin and mucous membranes. The information contained in this section is not intended to be a complete guide for all symptoms or conditions. If Swallowed: Do not induce vomiting. Regu-Mate may be given to treat a variety of diseases affecting the skin and mucous membranes. The information contained in this section is not intended to be a complete guide for all symptoms or conditions.

Regu-Mate (altrenogest) Solution 0.22% is readily absorbed systemically in animals, and the rapid intravenous route is contraindicated in management of potassium depleting diuretics which may cause symptomatic hypokalemia.

Regu-Mate (altrenogest) Solution 0.22% is readily absorbed systemically in animals, and the rapid intravenous route is contraindicated in management of potassium depleting diuretics which may cause symptomatic hypokalemia. The information contained in this section is not intended to be a complete guide for all symptoms or conditions. If Swallowed: Do not induce vomiting. Regu-Mate may be given to treat a variety of diseases affecting the skin and mucous membranes. The information contained in this section is not intended to be a complete guide for all symptoms or conditions.
PANACUR
Internet/Mark Animal Health
(fenbendazole)

**DESCRIPTION:**
Panacur® (fenbendazole) Paste 10% contains the active ingredient, fenbendazole. The chemical name of fenbendazole is methyl 5-(phenylthio)-2-benzimidazole carbamate.

The chemical structure is:

Each gram of Panacur® (fenbendazole) Paste 10% contains 100 mg of fenbendazole and is flavored with artificial apple-cinnamon liquid.

**ACTIONS:**
The anthelmintic action of Panacur® (fenbendazole) Paste 10% is believed to be due to the inhibition of energy metabolism in the parasite.

**INDICATIONS:**
Panacur® (fenbendazole) Paste 10% is indicated for the control of large strongyls (Strongylus edentatus, *S. vulgaris*, *S. equorum*), encysted early third stage (hyobiotic), late third stage and fourth stage cyathostome larvae, small strongyles, pinworms (*Oxyuris equi*), ascarioses (*Parascaris equorum*), and larva-cordalis caused by fourth stage larva of Strongylus vulgaris in horses.

Panacur® (fenbendazole) Paste 10% is approved for use concomitantly with an approved form of trihydroxyfluran. Trihydroxyfluran is approved for the treatment of stomach bots (Gastrophilus intestinalis) in horses. Refer to the manufacturer’s label for directions for use and caution for trihydroxyfluran.

**PRECAUTIONS:**
Side effects associated with Panacur® (fenbendazole) Paste 10% could not be established in well-controlled safety studies in horses with single doses as high as 454 mg/lb (1,000 mg/kg) and 13 consecutive daily doses of 22.7 mg/lb (50 mg/kg). Particularly with higher doses, the lethal action of Panacur® (fenbendazole) Paste 10% may cause the release of antigens by the dying parasites. This phenomenon may result in either a local or systemic hypersensitive reaction. As with any drug, these reactions should be treated symptomatically. Panacur® (fenbendazole) Paste 10% has been evaluated for safety in pregnant mares during all stages of gestation with doses as high as 7.4 mg/lb (15 mg/kg) and in stallions with doses as high as 1.4 mg/lb (25 mg/kg). No adverse effects on reproduction were detected. The recommended dose for control of 4th stage larvae of Strongylus vulgaris, 4.6 mg/lb (90 mg/kg) daily for 5 consecutive days, has not been evaluated for safety in stallions or pregnant mares.

**Internal Parasites:**
Regular deworming at intervals of six to eight weeks may be required due to the possibility of reinfection.

**Migrating Tissue Parasites:**
In the case of 4th stage larva of *Strongylus vulgaris*, treatment and retreatment should be based on the life cycle and the epidemiology. Treatment should be initiated in the spring and repeated in the fall after a six month interval.

Optimum Deworming Program for control of Strongylus vulgaris should be performed.

Optimum Deworming Program for control of *S. vulgaris*:

**Reduction of S. vulgaris infections is achieved by reducing the infectivity of the parasites.**

When horses are running on pasture, in temperate North America, maximum pasture infectivity occurs in October-December. If horses are removed from those pastures in January, pasture infectivity will decline to zero by July 1. Egg production of *S. vulgaris* is minimal from January through April, peaking in August and declining to minimal values in December.

Recommended Deworming Program:

1. **December 1**
   - **February 1**
   - **April 1**
   - **June 1**
   - **August 1**

1. **October 1**

**The two treatments that are in bold type are the recommended periods when the 5 day treatment regimen for the control of the migrating larva of *S. vulgaris* should be performed.**

**For other areas in the USA with a 3-month retreatment period for the migrating larvae of *S. vulgaris* may be different; consult with your veterinarian.**

**CAUTIONS:**
Keep this and all medications out of the reach of children.

When using Panacur® (fenbendazole) Paste 10% concomitantly with trihydroxyfluran, refer to the manufacturer’s label’s use and caution for trihydroxyfluran.

**WARNING:** Do not use in horses intended for human consumption.

**DOSAGE:**
Panacur® (fenbendazole) Paste 10% is administered orally at a rate of 3 mg/lb (6 mg/kg) for the control of large strongyls, small strongyles, and pinworms. One syringe will deworm a 1,000 lb horse. For foals and weanlings (less than 18 months of age) where ascarioses are a concern, the recommended dose is 4.6 mg/lb (10 mg/kg); one syringe will deworm a 550 lb horse.

For control of encysted early third stage (hyobiotic), late third stage and fourth stage cyathostome larvae, and fourth stage larva of *Strongylus* vulgaris, the recommended dose is 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days; administer one syringe for each 550 lbs body weight per person.

**SEE PRECAUTIONS FOR RETREATMENT RECOMMENDATIONS.**

**DIRECTIONS FOR USE:**
1. Determine the weight of the horse.
2. Remove syringe tip.
3. Turn the dial ring until the edge of the ring nearest the tip lines up with zero.
4. Depress plunger to advance paste to tip.
5. Now set the dial ring at the graduation nearest the weight of the horse (do not overdosage).
6. Horse’s mouth must be free of food.
7. Insert nozzle of syringe through the intermaxillary space and deposit the paste on the back of the tongue by depressing the plunger.

**HOW SUPPLIED:**
Panacur® (fenbendazole) Paste 10% is supplied in 25 g syringes.

**Store at or below 25°C (77°F).**

**CONSIDER YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS, TREATMENT AND CONTROL OF PARASITISM.**

Made in France

**Distributed by Intervet Inc. (a/b thyroid Merck Animal Health), Summit, NJ 07901**

**NADA # 120-648, Approved by FDA**

**For use in animals only,**

**Restricted Drug (California) - Use only as Directed 147109-B2**

**CPN:** 1047513.0

**EQUINE SALES TEAM**
Ron McDaniel
Director, Equine Sales
Amy Lenhart
402-672-8146
Inside Sales, New England
Jeff Baldridge
308-530-0407
IA, KS, MO, MN, ND, NE, SD
Kip Boule
407-448-2722
FL, GA
Deanna Chapman
319-480-5577
AR, LA, MS, OK, NE, TX
Booth Farrell
443-696-1010
DE, MD, NJ, E, PA, NY, N, WY
John Ford
730-666-5635
CO, ID, MT, WY
Pete Hale
512-917-1998
NM, TX, SW, LA
Jennifer Little
916-201-4418
AK, N, CA, N, NV, OR, WA
Steve Montemarano
740-972-6554
IL, IN, MI, OH, W, PA, WI
Michelle Simpson
859-309-4369
KY, N, MS, TN
Jessica Steffen
559-927-0505
S, CA, AZ, S, NV, UT, HI
Andrew Stetson
919-448-7039
NC, SC, S, W, VA

**EQUINE PROFESSIONAL SERVICES**
866-349-3497

D. Craig Barnett, DVM
Earl Gaughan, DVM, Dipl. ACVS
Bryant Craig, DVM
Fairfield Bain, DVM, M.B.A., Dipl. ACVIM, ACVPR, ACVECC
Duane Chappell, DVM
Christina Taylor, RVT

**MARKETING**
Kathy Marianowicz
Marketing Manager

**CUSTOMER SERVICE**
800-521-5767

Merck Animal Health
2 Giralda Farms • Madison, NJ 07940
www.merck-animal-health-equine.com

**Merck Animal Health**
2 Giralda Farms • Madison, NJ 07940 • merck-animal-health-usa.com • 800-521-5767

**Copyright © 2019 Intervet Inc., a subsidiary of Merck & Co., Inc.**

**All rights reserved. US EQV-11900004**

**The Science of Healthier Animals**